Cantargia AB (publ) (FRA:7V3)

Germany flag Germany · Delayed Price · Currency is EUR
0.351
-0.003 (-0.85%)
At close: Dec 4, 2025
154.16%
Market Cap 86.22M
Revenue (ttm) 27.92M
Net Income (ttm) 12.66M
Shares Out n/a
EPS (ttm) 0.05
PE Ratio 6.81
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume n/a
Average Volume 209
Open 0.351
Previous Close 0.354
Day's Range 0.351 - 0.351
52-Week Range 0.064 - 0.355
Beta n/a
RSI 63.31
Earnings Date Nov 19, 2025

About Cantargia AB

Cantargia AB (publ), a biotechnology company, develops pharmaceuticals for treatment of cancer, inflammatory, and autoimmune diseases. The company is developing CAN04 (nadunolimab), an antibody that can bind IL1RAP, which is in phase II clinical trial for the treatment of pancreatic cancer, non-small cell lung cancer, and triple-negative breast cancer; and CAN10, an antibody against IL1RAP, which is in phase 1 clinical trial for the treatment of autoimmune and inflammatory diseases, including systemic sclerosis and myocarditis. It also develops... [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 2009
Employees 22
Stock Exchange Frankfurt Stock Exchange
Ticker Symbol 7V3
Full Company Profile

Financial Performance

Financial numbers in SEK Financial Statements

News

There is no news available yet.